JAY LENTZNER: Open Payments
NPI 1982884904 · LONG BEACH, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,026 in 39 payments from 10 companies in 2025. Trend: 2023 $4,752 · 2024 $4,780 · 2025 $1,026
Food & beverage: $1,026
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 8 | $301 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $140 |
| Otsuka America Pharmaceutical, Inc. | 5 | $124 |
| ABBVIE INC. | 5 | $109 |
| Vanda Pharmaceuticals Inc. | 5 | $105 |
| Lundbeck LLC | 3 | $74 |
| Neurocrine BioSciences, Inc. | 2 | $62 |
| Alkermes, Inc. | 2 | $49 |
| Teva Pharmaceuticals USA, Inc. | 1 | $32 |
| Axsome Therapeutics, Inc. | 1 | $29 |
Products named: REXULTI, INVEGA SUSTENNA, CAPLYTA, SPRAVATO, VRAYLAR, FANAPT, INGREZZA, ARISTADA.
Industry payments across CA — which companies pay providers there.
